Novavax Shares Pop Another 50% Following Sanofi Deal
By Ben Glickman
Shares of Novavax continued their ascent on Monday, adding to gains from last week after the company announced a licensing deal with Sanofi.
The stock was up 50% to $13.31 in afternoon trading, reaching its highest intraday level since December 2022. Shares roughly doubled on Friday following the news, and are now up more than threefold in the last three months.
Novavax said Friday morning that it had agreed to a licensing deal with Sanofi to commercialize its Covid-19 vaccine worldwide. The company said it would receive up to $1.4 billion under the deal, inclusive of milestone payments.
Sanofi will have the sole license to use the Covid-19 vaccine in combination with its flu vaccine.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
May 13, 2024 14:14 ET (18:14 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks